{"title":"Correlation of serum thyroid hormone level with recurrence in patients with breast cancer after radical mastectomy","authors":"Hai-bin Lu, Xiaozhong Ji","doi":"10.3760/CMA.J.CN115355-20190909-00408","DOIUrl":null,"url":null,"abstract":"目的 \n探讨乳腺癌根治术后患者血清甲状腺激素(TH)水平变化及其与术后复发的相关性。 \n \n \n方法 \n选取2017年1月至2019年1月于江苏省海安市人民医院行乳腺癌根治术的患者112例为乳腺癌组,选取同期健康体检者60名为对照组,采用化学发光免疫法测定两组血清促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离四碘甲状腺原氨酸(FT4)、总四碘甲状腺原氨酸(T4)、总三碘甲状腺原氨酸(T3)水平。根据术后复发情况分为复发组和未复发组,比较两组血清TH水平。 \n \n \n结果 \n乳腺癌组术前血清T3、FT3及FT4水平[(1.58±0.27)nmol/L、(4.42±0.49)pmol/L、(9.68±1.26)pmol/L]均低于对照组[(2.05±0.33)nmol/L、(4.94±0.58)pmol/L、(11.17±1.65)pmol/L](均P<0.05),术后血清T3、FT3及FT4水平[(1.96±0.30)nmol/L、(4.75±0.51)pmol/L、(10.52±1.37)pmol/L]均高于术前(均P<0.05)。TNM分期Ⅰ期患者血清T3、FT3及FT4水平高于Ⅱ、Ⅲ期患者(均P<0.05),Ⅱ期患者血清T3、FT3及FT4水平高于Ⅲ期患者(均P<0.05)。乳腺癌患者未复发组术前血清T3、FT3及FT4水平均高于复发组(均P<0.05)。 \n \n \n结论 \nT3、FT3及FT4水平随疾病进展进行性降低,乳腺癌根治术后由于病灶组织的清除引起神经递质的改变,从而导致血清T3、FT3及FT4水平的增加,复发患者T3、FT3及FT4水平低于未复发患者,考虑乳腺癌复发与甲状腺功能异常有关。","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"32 1","pages":"192-195"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115355-20190909-00408","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Objective To investigate the changes of serum thyroid hormone (TH) level in patients with breast cancer after radical mastectomy and its correlation with postoperative recurrence. Methods A total of 112 patients with breast cancer who underwent radical mastectomy in Hai'an People's Hospital of Jiangsu Province from January 2017 to January 2019 were selected as the breast cancer group, and 60 health examinees in the same period were selected as the control group. Serum thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free tetraiodothyronine (FT4), total tetraiodothyronine (T4) Total triiodothyronine (T3) levels. Divide into recurrent group and non recurrent group based on postoperative recurrence, and compare the serum TH levels between the two groups. Results The preoperative serum T3, FT3 and FT4 levels [(1.58 ± 0.27) nmol/L, (4.42 ± 0.49) pmol/L, (9.68 ± 1.26) pmol/L] in the breast cancer group were lower than those in the control group [(2.05 ± 0.33) nmol/L, (4.94 ± 0.58) pmol/L, (11.17 ± 1.65) pmol/L] (all P<0.05). The postoperative serum T3, FT3 and FT4 levels [(1.96 ± 0.30) nmol/L, (4.75 ± 0.51) pmol/L, (10.52 ± 1.37) pmol/L] were all lower. It was higher than that before operation (all P<0.05). The serum levels of T3, FT3, and FT4 in TNM stage I patients were higher than those in stage II and III patients (all P<0.05), while the serum levels of T3, FT3, and FT4 in stage II patients were higher than those in stage III patients (all P<0.05). The preoperative serum T3, FT3 and FT4 levels in the non recurrence group of breast cancer patients were higher than those in the recurrence group (all P<0.05). Conclusion The levels of T3, FT3 and FT4 gradually decrease with the progression of the disease. After radical surgery for breast cancer, the clearing of the focus tissue causes the change of neurotransmitters, which leads to the increase of serum T3, FT3 and FT4 levels. The levels of T3, FT3 and FT4 in recurrent patients are lower than those in non recurrent patients. It is considered that the recurrence of breast cancer is related to thyroid dysfunction.
期刊介绍:
"Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association.
It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.